Simplify Propel Opportunities ETF Rating $24.70 +0.47 (+1.94%) (As of 11/4/2024 ET) Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsRatings Simplify Propel Opportunities ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.SURI Aggregate RatingModerate Buy2.77Holdings in SURI have an aggregate rating of Moderate Buy based on 130 analyst ratings issued in the past year covering 19 companies (96.0% of the portfolio).SURI Aggregate Price Target$39.4859.83% UpsideHigh Prediction$50.26Average Prediction$39.48Low Prediction$27.16Holdings in SURI have an aggregate price target of $39.48 and a range of $27.16 to $50.26 covering 19 companies (96.0% of the portfolio).SURI Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy9 Buy rating(s)Moderate Buy7 Moderate Buy rating(s)Hold3 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Simplify Propel Opportunities ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 19 SURI Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings23.33%APLTApplied Therapeutics$9.26+1.9%4.2264 of 5 stars3.17$12.50 35.0%622.56%PAGPPlains GP$17.84+2.9%3.2147 of 5 stars2.30$20.00 12.1%10Upcoming Earnings8.13%PHATPhathom Pharmaceuticals$18.94+3.7%1.5306 of 5 stars2.75$22.50 18.8%4Upcoming Earnings6.76%AKROAkero Therapeutics$32.05-0.9%3.8751 of 5 stars2.86$43.20 34.8%7Upcoming EarningsInsider Selling5.82%RNAAvidity Biosciences$44.82+7.0%2.0077 of 5 stars3.00$63.22 41.1%95.28%TCRXTScan Therapeutics$5.08+2.6%1.4918 of 5 stars3.00$12.00 136.2%5Positive News4.70%MDGLMadrigal Pharmaceuticals$331.32+3.7%3.8936 of 5 stars2.69$344.33 3.9%13Earnings ReportAnalyst ForecastAnalyst RevisionHigh Trading Volume4.41%TSATTelesat$12.51-0.7%0.9507 of 5 stars2.00$9.00 -28.1%1News Coverage3.86%ARDXArdelyx$5.89-3.3%4.192 of 5 stars3.00$11.67 98.1%8Analyst ForecastOptions VolumeAnalyst Revision2.64%ABEOAbeona Therapeutics$6.04-3.4%3.4313 of 5 stars3.00$18.00 198.0%3Upcoming Earnings1.53%SNDXSyndax Pharmaceuticals$18.94-0.2%3.898 of 5 stars2.90$35.90 89.5%10Upcoming Earnings1.39%KURAKura Oncology$17.81+5.5%3.7928 of 5 stars3.00$28.83 61.9%8Upcoming EarningsAnalyst Forecast1.35%KYMRKymera Therapeutics$47.07+1.3%0.8303 of 5 stars2.80$50.93 8.2%15Earnings ReportAnalyst ForecastAnalyst RevisionNews Coverage1.06%ACHVAchieve Life Sciences$4.74+0.6%0.7535 of 5 stars3.25$15.50 227.0%4Upcoming Earnings0.98%ZVRAZevra Therapeutics$8.55+1.8%2.8459 of 5 stars3.13$20.83 143.7%80.72%CMPSCOMPASS Pathways$4.68-1.5%2.2525 of 5 stars3.00$30.67 555.3%7Earnings ReportAnalyst Forecast0.64%ATHAAthira Pharma$0.64+4.9%2.7112 of 5 stars2.00$13.83 2,061.8%4News CoverageGap DownHigh Trading Volume0.55%CASHPathward Financial$70.78-0.7%1.5292 of 5 stars2.50$74.50 5.3%2Positive News0.28%VRCAVerrica Pharmaceuticals$1.43-6.5%4.2001 of 5 stars2.67$11.40 697.2%6Gap Up This page (NYSEARCA:SURI) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Simplify Propel Opportunities ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Simplify Propel Opportunities ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
